Successful treatment of severe psoriasis relapse with secukinumab (interleukin 17 A inhibitor) after abrupt brodalumab (interleukin 17 receptor inhibitor) discontinuation: A retrospective study evaluating long-term efficacy and safety - 19/09/18
Doi : 10.1016/j.jaad.2018.03.027
Abdallah Khemis, MD a, Awatef Kelati, MD a, Henri Montaudié, MD a, Jean-Philippe Lacour, MD a, Thierry Passeron, MD, PhD a, b, ⁎ 
a Department of Dermatology, Centre Hospitalier Universitaire Nice, Université Nice Côte d'Azur, Nice, France
b Team 12, C3M, Institut National de la Santé et de la Recherche Médicale U1065, Université Nice Côte d'Azur, Nice, France
∗Correspondence to: Thierry Passeron, MD, PhD, Department of Dermatology, Hôpital de l'Archet 2, CHU de Nice, 150 route de Ginestière 06202, Nice, FranceDepartment of DermatologyHôpital de l'Archet 2CHU de Nice150 route de Ginestière 06202NiceFrance
| Funding sources: None. |
|
| Conflicts of interest: Drs Khemis, Lacour, and Passeron have been investigators with Amgen, Abbvie, Celgene, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, and UCB Pharma. |
|
| Dr Khemis has received honoraria and travel expenses from Abbvie, Amgen, Janssen, Celgene, LEO Pharma, Lilly, MSD, Novartis, Pfizer, and UCB Pharma. Dr Lacour has received honoraria and travel expenses from Abbvie, Amgen, Janssen, Celgene, LEO Pharma, Lilly, MSD, Novartis, Pfizer, and UCB Pharma. Dr Passeron has received honoraria and travel expenses from Abbvie, Celgene, Janssen, LEO Pharma, Lilly, MSD, Novartis, and Pfizer. Dr Montaudié has received honoraria and travel expenses from Abbvie, Celgene, Lilly, Merck, Pfizer, ROCHE, and BMS. Dr Kelati has no conflicts of interest to disclose. |
|
| Reprints not available from the authors. |
© 2018
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 79 - N° 4
P. 758-760 - octobre 2018 Retour au numéro
Article précédent
- Demographics and outcomes of microcystic adnexal carcinoma
- Brian J. King, Stanislav N. Tolkachjov, Daniel S. Winchester, Christian L. Baum, Jerry D. Brewer, Christopher J. Arpey, Clark C. Otley, Randall K. Roenigk
- Drug survival of apremilast in patients treated for psoriasis in a real-world setting
- Erica B. Lee, Mina Amin, Jashin J. Wu
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?